Aleva Neurotherapeutics is positioned in the DBS hardware segment with a MEMS-based directional lead design that offers finer current steering than conventional cylindrical electrodes, targeting improved side-effect profiles in Parkinson's and essential tremor. With CE marking and Series C+ funding, it sits further along the commercialization curve than most neuromodulation startups but faces entrenched competition from Medtronic, Abbott, and Boston Scientific.